Poplar Therapeutics
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $50M
Overview
Developing next-generation AAV gene therapies for severe neurological and rare genetic diseases.
Gene TherapyRare DiseaseNeuroscience
Technology Platform
A next-generation AAV gene therapy platform featuring engineered capsids for improved tissue targeting and reduced immunogenicity.
Funding History
1Total raised:$50M
Series A$50M
Opportunities
Potential to address diseases untreatable by first-generation AAV therapies due to delivery or immune response challenges.
Risk Factors
High development costs, complex manufacturing, and clinical risks associated with novel AAV capsids and gene therapy overall.
Competitive Landscape
Enters a crowded gene therapy field with many players targeting rare neurological diseases, requiring clear vector differentiation.